Sarcoid-like reaction and hypothyroidism induced by PD-1 inhibitor treatment in metastatic renal cell carcinoma: a case report and literature review

Oadi N. Shrateh,Yazan Abugharbieh,Yousef Abu Asbeh,Hani hour,Iyad Awad,Sami bannoura
DOI: https://doi.org/10.1186/s12890-024-02943-9
IF: 3.1
2024-03-09
BMC Pulmonary Medicine
Abstract:Pembrolizumab is among the approved treatments for a variety of cancer types, including clear cell renal cell carcinoma (ccRCC). It has contributed to enhancing the prognosis of renal cell carcinoma. However, it is essential to be aware of the numerous potential immune-related side effects associated with its use.
respiratory system
What problem does this paper attempt to address?